Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Viana Mancuzo (Belo Horizonte (MG), Brazil), R. Celia Carlos Tibana (São Paulo, Brazil), M. Soares (São Paulo, Brazil), D. Dos Reis Estrella (Belo Horizonte (MG), Brazil), C. Pereira (São Paulo, Brazil). Predictive Findings of survival in Familiar Pulmonary fibrosis. 2250

Member's Comments

No comment yet.

Related content which might interest you: Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Quantitative Assessment of Thoracic Muscles in Patients with Idiopathic pulmonary fibrosis :Relationship with Prognosis Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 PP219 – Development and Validation of a Novel Prognostic Nomogram for COPD patients with Pulmonary Hypertension Source: ERS Lung Science Conference 2021 Year: 2021 Six-minute walk test desaturation and echocardiographic findings in IPF: Correlational observations made in the European IPF registry (eurIPFreg) Source: International Congress 2014 – ILDs 2 Year: 2014 Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Prognostic value of outcome variables at follow-up in patients with PAH Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Exercise Pulmonary Vascular Resistances are Predictors of Survival in Systemic Sclerosis Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity Year: 2013 Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014